Prophylaxis News and Research

RSS

Cases of malaria increasing in UK

A huge rise in the numbers of UK residents travelling to malaria endemic areas, combined with a failure to use prevention measures, has significantly increased cases of imported falciparum malaria in the UK over the past 20 years, according to a study published on BMJ.com.

3 Jul 2008

Quick responses to influenza outbreaks reduces illness and death

Influenza outbreaks were shorter and resulted in fewer cases and fewer deaths at long-term care facilities that started residents on preventive antiviral medications within five days of the first case, compared to those that started later, according to a new study in the July 1 issue of Clinical Infectious Diseases, currently available online.

11 Jun 2008

Three bitten by rabid dog in Britain

A dog imported into Britain from Sri Lanka has died of rabies but not before it had bitten three people.

28 Apr 2008

Simplified economical method of giving rabies vaccine

A simplified economical method of giving rabies vaccine is just as effective as the expensive standard vaccine regimen at stimulating anti-rabies antibodies.

23 Apr 2008

Damaged veins heal faster with heparin treatment, laboratory study finds

A commonly used medication that prevents blood clots from forming may also prevent existing clots from damaging delicate vein walls and may accelerate healing in a clot-damaged area of vein wall, according to new research from the University of Michigan Cardiovascular Center.

14 Mar 2008

New findings do not support recommendation for universal screening on hospital admission for MRSA

New findings do not support the recommendation for universal screening on hospital admission for methicillin-resistant Staphylococcus aureus (MRSA) to reduce the rate of hospital-acquired infections in surgical patients, according to a study in the March 12 issue of JAMA.

12 Mar 2008

Pandemic influenza could be mitigated if measures were implemented quickly

An outbreak of pandemic influenza in the U.S. could be mitigated with prompt implementation of social-distancing measures combined with antiviral treatment and prophylaxis until a vaccine is available, according to new findings published in the online Early Edition of PNAS.

10 Mar 2008

FDA approves Aloxi injection for prevention of postoperative nausea and vomiting

Eisai Corporation of North America, its U.S. subsidiary, MGI PHARMA, INC., and Helsinn Healthcare SA today announced that the U.S. Food and Drug Administration (FDA) has approved Aloxi (palonosetron hydrochloride) injection for the prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery.

4 Mar 2008

Tenofovir gel safe for daily use over an extended period

A vaginal microbicide that incorporates an antiretroviral (ARV) drug normally used to treat people with HIV is safe for sexually active HIV-negative women to use every day over an extended period, suggest results of a clinical trial of tenofovir topical gel.

27 Feb 2008

XYNTHA approved for teatment of hemophilia A by FDA

Wyeth Pharmaceuticals, a division of Wyeth ( NYSE:WYE) , announced today that it has received approval from the U.S. Food and Drug Administration for XYNTHA(TM) (Antihemophilic Factor [Recombinant], Plasma/Albumin-Free), a recombinant factor VIII product, for patients with hemophilia A for both the control and prevention of bleeding episodes and surgical prophylaxis.

22 Feb 2008

Mouse model shows potential efficacy of HIV prevention strategy

A new kind of laboratory mouse can be used to test the efficacy of much-needed methods to prevent transmission of HIV, the virus that causes AIDS, according to research by J. Victor Garcia and colleagues at the University of Texas Southwestern Medical Center in Dallas.

15 Jan 2008

Anti-retrovirals given daily before and after exposure to HIV prevent vaginal transmission AIDS virus

Prescription drugs now used to treat human immunodeficiency virus infection in adults may prevent the vaginal transmission of HIV, researchers at UT Southwestern Medical Center have found.

15 Jan 2008

Baxter to develop recombinant Factor IX proteins to treat hemophilia B

Baxter International Inc. has announced that it has initiated pre-clinical programs to develop recombinant Factor IX proteins to treat hemophilia B.

From Baxter International Inc. 7 Jan 2008

Sanofi Pasteur enters agreement eith Crucell for next-generation biologicals against rabies

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has signed an exclusive collaboration and commercialization agreement with Crucell N.V. for Crucell's rabies monoclonal antibodies (MAbs), next-generation rabies biologicals to be used in association with rabies vaccine for post-exposure prophylaxis against this fatal disease.

4 Jan 2008

New therapy reduces mortality in patients with severe COPD

Patients with severe COPD may benefit more from therapy that combines salmeterol and fluticasone [SFC] than treatment with tiotropium, according to results from a long-term, multi-center study, "Investigating New Standards for Prophylaxis in Reducing Exacerbations" (INSPIRE) that directly compared the two therapies.

2 Jan 2008

New therapeutic options for newly diagnosed multiple myeloma patients

Mayo Clinic researchers presented results of a phase II trial of myeloma induction therapy -- a first step therapy designed to reduce cancer cells numbers -- with cyclophosphamide, bortezomib, and dexamethasone (Cybor-D) showing an improved response over the traditional lenalidomide-dexamethasone (L-Dex) therapy.

10 Dec 2007

Immtech and BioAlliance sign agreement on Pafuramidine for African sleeping sickness

Immtech Pharmaceuticals has announced that the Company has granted an exclusive license to BioAlliance Pharma SA to commercialize Immtech's oral drug, pafuramidine maleate (pafuramidine), in Europe for the treatment of pneumocystis pneumonia (PCP) in AIDS patients and for the treatment of Human African trypanosomiasis, also known as African sleeping sickness.

5 Dec 2007

Isotechnika granted Norwegian patent for lead immunosuppressive drug

Isotechnika Inc. has announced that the Company has been issued Norwegian Patent No. 324042 for its lead immunosuppressive drug, ISA247.

27 Nov 2007

Nanoviricide drug candidate effectiveness confirmed against rabies and influenzas

NanoViricides, Inc. has said that in a confirmatory study, their nanoviricide drug candidates exhibited a consistent 20% to 30% survival in the test animals.

13 Nov 2007

Novel strategy to inactivate encephalitis virus

A collaborative team of scientists from the Uniformed Services University of the Health Sciences (USU) and the National Cancer Institute (NCI) have developed a novel strategy to inactivate highly virulent Venezuelan equine encephalitis virus (VEEV) that can infect and kill both animals and humans.

31 Oct 2007